Get started
Live feed
·
PRReleasevia Quantisnow
Oric Pharmaceuticals Inc. logo

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
Oric Pharmaceuticals Inc. logo
ORIC
Oric Pharmaceuticals Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2020
Follow ORICFull ORIC profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORIC (Oric Pharmaceuticals Inc.) and more on Quantisnow.